Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 10/20 | 0.40 |
| ▸ | CXCR1 | P25024 | 8/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9979940 | 0.86 | LMNA (0.41) | SPRCXCR2MEN1LMNAKMT2A | |
| SCHEMBL9979957 | 0.85 | MAPK14 (0.48) | SPRCXCR2MEN1LMNAKMT2A | |
| SCHEMBL9980036 | 0.84 | CXCR2 (0.52) | CXCR2 | |
| SCHEMBL9979928 | 0.77 | SPR (0.46) | SPRCRBN | |
| SCHEMBL9979995 | 0.73 | SPR (0.44) | SPRHTTKMT2ASMN1; SMN2CRBN | |
| SCHEMBL30515699 | 0.73 | CXCR2 (0.47) | SPRCXCR2CXCR1 | |
| SCHEMBL9980065 | 0.73 | CXCR2 (0.47) | SPRCXCR2CXCR1 | |
| SCHEMBL9980086 | 0.71 | CXCR2 (0.74) | CXCR2CXCR1 | |
| SCHEMBL9979984 | 0.71 | CXCR2 (0.74) | CXCR2CXCR1 | |
| SCHEMBL9980082 | 0.70 | SPR (0.41) | SPRCXCR2CXCR1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651891-B1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-8648118-B2 | Bicyclic ring system substituted amide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012080456-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | CXCR2, CCR2, CCR1 | SPR 3856/4885CXCR2 1/4885CXCR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.